MDDX, INC.

Medtech · Acquired

Autoantibody-based blood biomarker panel for early detection of ovarian and endometrial cancers

Grants
$700K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a biomarker panel for minimally-invasive screening and diagnosis of gynecological disease$299,998
Federal grantDepartment of Health and Human Services · Phase I · Development of a biomarker panel for screening and early detection of gynecological cancers$399,972
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1792DANDELION SCIENCE CORP——
1793NEURALTRAK, INC——
1794Atocera, Inc.——
1795MDDX, INC.——
1796Recombinant Technologies LLC——
1797GAIA MEDICAL INSTITUTE, LLC, THE——
1798PRECISION MEMBRANES, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.